Latest Secondary Hyperparathyroidism (SHPT) News
No new safety concerns observed in a 52-week extension trial of etelcalcetide in hemodialysis with secondary hyperparathyroidism.
Paricalcitol-based protocol includes limited use of calcium-based phosphate binders.
The control of phosphorus is underappreciated, for example.
Researchers found insignificant differences between the 2 surgeries in SHPT persistence and recurrence.
Treatment with the medication reduced the risk of death by half among patients with iPTH of 500 pg/mL or above.
An academic hemodialysis center realized cost savings from vitamin D receptor activator therapy after converting to oral calcitriol -- without negative impact on SHPT control.
Iranian study of hemodialysis patients with secondary hyperparathyroidism finds no significant correlation.
Intact parathyroid hormone levels fell significantly in all patients who underwent total Ptx with autotransplant and 91.6% of subtotal Ptx patients.
The non-surgical approach effectively lowered serum parathyroid hormone levels in the short term, but not to the same extent as surgery.
A higher proportion of cinacalcet than placebo recipients met the primary efficacy endpoint of PTH levels of 250 pg/mL or less (25.4% vs. 3.5%).
Among other findings, patients taking statins had more than twice the odds of SHPT.
High intact parathyroid hormone levels were associated with a lower estimated glomerular filtration rate.
Small case series also confirmed that the diagnosis of calciphylaxis is rarely made in the nodular, non-ulcerative phase.
In a study, ioPTH decay at 30 minutes post-excision was highly accurate in predicting persistent SHPT.
Study finds a 20% to 25% lower risk for early death over the long term.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)